Insider Purchases: Inside the Buy
Tag: healthcare stocks
Elite Buys Ely: Should You Buy Lilly’s Stock Too?
Eli Lilly insiders are opening their wallets after the company crushed Q2 2025 — revenue up 38%, EPS up 92%, and blockbuster drugs Zepbound and Mounjaro fueling a raised guidance. Institutions are all-in, the pipeline is buzzing, but the valuation is sky-high. Is LLY worth chasing at $639, or is patience the better prescription?
Centene (CNC): CEO Buys at $25, Earnings Bleed Red, and the Stock’s on Life Support — Bargain or Bust?
Centene (CNC) just got a shot in the arm from its CEO and a director buying nearly $740K worth of stock near decade lows. But with Q2 earnings bleeding red, rising Medicaid costs, and valuation sliced in half, is this a bargain-bin opportunity or just a patient in the ICU?
Moderna (MRNA): The Biotech Rollercoaster – Will This Gene Editor Reach the Top? 🎢💉
Moderna (MRNA) might be on the downhill since its peak in 2021, but its remarkable mRNA platform is fueling new therapeutic breakthroughs. With strong insider bets, a healthy pipeline, and institutional backing, Moderna could be an intriguing long-term play for investors. However, risks like intense competition and COVID sales deceleration remain. Should you bet on Moderna’s future or stay on the sidelines? Here’s what you need to know.